The site of negative selection in the thymus has been Inferred from a range of different experiments. Analysis of thymic deletion of Vp5 + , Vp11 + or Vp17a + cells in H-2E transgenic mice led to the theory that negative selection occurs predominantly in the medulla (specifically, through presentation by medullary dendritic cells). Other experiments investigated whether transgenic TCR are deleted at the double-positive (DP) or single-positive stage following encounter with peptide ligand: by flow cytometric analysis deletion is generally found to occur at the DP thymocyte stage and as these cells are found predominantly in the cortex, it has been inferred that this Is the key site of negative selection. The visualization of apoptotic thymocytes In situ has recently been reported for specific examples of negative selection. Using a panel of TCR transgenic lines In which negative selection occurs at different stages of thymocyte development, we have used TUNEL staining to analyse the anatomical sites of thymocyte apoptosis. For the first time we have been able to compare directly the sites of deletion induced by the endogenous cognate peptides or by endogenous superantigen. We show that generalization from the medullary deletion of Vp5 + , Vp11 + or Vp17a + cells by the endogenous superantigens Mtv 8 and 9 and from limited examples of cortical deletion by exogenous peptide administered to TCR transgenic mice is over-simplified. Apoptotic thymocytes in mice lacking Mtv superantigens are indeed localized in the cortex. However, when deletion is induced by cognate self peptide, apoptosis can occur in the cortex, the medulla or at the junction between the two.
Introduction
The mechanism by which TCR engagement of ligand can lead to either positive or negative selection has long been debated. One central hypothesis, the 'differential avidity hypothesis', is that these processes result from engagement of the TCR at different avidities. Recent studies strongly suggest that such differences in the avidity of the TCR for the peptide-MHC complex are sufficient alone to account for the fate of thymocytes (1) (2) (3) (4) . These studies investigate the effects of exogenous peptides added to fetal thymic organ cultures but cannot address the issues of the site of peptide presentation nor the nature of endogenous thymic peptides presented.
The other key hypothesis, often termed 'the altered ligand hypothesis', argues that positive or negative selection is determined by presentation of self peptides by different cell types. An anatomical distinction between positive and negative selection was first suggested by chimera experiments showing that whereas positive selection is mediated by thymic epithelial cells, negative selection requires expression of MHC by dendritic cells, abundant in the medulla (5) .
The first two authors contributed equally to this work. Mice expressing a transgenic H-2E molecule in different thymic compartments were then used to show that transgene expression by bone marrow-derived cells of the medulla is sufficient for negative selection and by cortical epithelium for positive selection (6) (7) (8) (9) . Many of these experimental models, commonly investigating the H-2E-dependent deletion of T cells utilizing Vp5, 11 or 17a, involved deletion by Mtv 8 and 9 endogenous superantigens rather than cognate antigen. However, other data, derived principally from flow cytometric analysis of TCR transgenic mice, show that negative selection of self-reactive thymocytes generally acts on double-positive (DP) thymocytes (10) . Since DP cells are predominantly cortical, it is assumed from these experiments that negative selection occurs in the cortex. Thus one body of evidence shows negative selection to occur in the medulla while another places it in the cortex. Yet another possibility is offered by a study on deletion of Vp6 transgenic receptors in the presence of Mtv 7, localizing negative selection to the cortico-medullary junction (11) Negative selection was visualized in situ, rather than by inference from CD4/CD8 phenotypes, by Surh and Sprent using dUTP labelling of apoptotic nuclei in thymus (12) . Taking the example of endogenous superantigen-mediated Vp5 deletion in H-2E + mice, they showed directly that negative selection is a medullary event However, in two TCR transgenic lines given high doses of exogenous cognate peptide to delete self-reactive T cells, negative selection was observed in the cortex (13, 14) . Apoptosis was also detectable in the thymic cortex of MHC class I and class II double-knockout mice, a phenomenon which, by default, was attributed to 'death by neglect' (12) . Thus by in situ staining negative selection appears to be localized to distinct but various thymic compartments, yet the basis for these differences is unclear. To resolve these contradictions we undertook a comprehensive analysis of the sites of negative selection in a series of TCR transgenic lines in which we varied the contribution from endogenous Mtv integrants. We have been able to compare negative selection by superantigen or cognate antigen, using deleting ligands that are, unlike previous studies, endogenous self peptides.
homozygous. Mice were housed in conventional conditions at the animal facilities of either the Clinical Research Centre or the National Institute for Medical Research, UK. All mice were cared for within the guidelines of the relevant institution.
Thymocyte preparations and FACS analysis
Thymuses were removed from 6-to 8-week-old mice, one lobe was immediately processed for immunohistochemistry as outlined below. The second lobe was made into a single cell suspension in a solution of PBS, 0.02% sodium azide and 10^g/ml rat Ig (Sigma, Dorset, UK). Cells (1x10 6 ) were stained with directly conjugated antibodies [fluoresceinconjugated KT15 (18) for CD8 and R-phycoerythrin-conjugated YTS19.1 for CD4 (Caltag, CA)] and analysed on either a FACScan (Becton Dickinson, Mountain View, CA) or an EPICS Elite ESP (Coulter Electronics, Hialeah, FL) The data were analysed with CELLQuest Software (Becton Dickinson). FACS profiles depicted are representative of extensive analysis of each line (a minimum of five mice per line described) As different samples were processed on different machines, the fluorescence intensity cannot be directly compared.
Immunohistochemistry and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labelling (TUNEL) staining
Thymuses removed from 6-to 8-week-old mice were immersed in OCT compound (RA Lamb, London, UK) and immediately frozen in isopentane in liquid nitrogen. Cryosections (5 |im) were cut, air-dried and fixed in ice-cold acetone. For TUNEL staining (19) , sections were incubated for 1 h with TdT and digoxigenin-conjugated dUTP in cacodylate buffer (Oncor, MD) After washing in PBS, sections were incubated with fluorescein-conjugated Fab antibody fragments specific for digoxigenin (Oncor) To stain for epithelial cells, sections were then incubated with A575 polyclonal rabbit anti-keratin antibody (Dako, Buckinghamshire, UK) and after washing, with mouse-adsorbed Texas Red-conjugated F(ab')2 donkey anti-rabbit lgG(H + L) (Stratech Scientific, Bedfordshire, UK). Sections were viewed with a confocal laser scanning Leica IR microscope (Leica, Heidelberg, Germany).
Methods

Mice
The A18.A transgenic line, specific for C5 complement component and H-2E k restricted, has been previously described (15) . The C6 line, specific for H-Y/H-2K k , was generated in CBA/Ca mice using a CD2 cassette (16) expressing the a and p TCR chains from the CD8 + T cell clone C6 (17) . This line was backcrossed to C58 mice for two generations and the resultant offspring were analysed by Southern blot for the presence of Mtvs 8 and 9. Those offspring having neither Mtv were intercrossed to establish the C58 backcross line. The A1(m-1) transgenic line was generated in CBA/Ca mice using a construct based on the TCR a and p of the CD4 + T cell clone A1, specific for H-Y/H-2E k (17) , and a derivative of the human CD2 cassette (16) (D. Zelenika et al., unpublished). All transgenic lines used in this study were hemizygous for the transgene except the A18 A transgenic mice which were
Results
Characterization of TCR transgenic lines
The C6 transgenic line expresses a Vp11 + receptor from an H-Y-specific H-2K k -restricted CD8 + clone (Fig. 1A and B C5~ background) in which positive selection of CD4 + cells occurs (Fig. 1E) (15) . In CBA/Ca mice positive for the C5 antigen (the C5 + background) (Fig. 1F) , there is negative selection of DP thymocytes, although at a later stage than in males of the H-Y/K k -specific C6 line, so that thymus size and cellularity is decreased in C5 + A18.A mice by -50%.
The sites of negative selection induced by antigen and superantigen are distinct
Staining for DNA strand breaks by TUNEL has been widely used as a marker of apoptosis and, in the case of developing thymocytes, of negative selection (12, 13, 19) . We have used TUNEL to identify the sites of negative selection in the transgenic mouse lines described above ( Fig. 2 and Table  1 ). We initially examined the sites of thymic apoptosis in H-2E + Czech mice lacking Mtv integrants (Fig. 2a ) (20) A minimal amount of apoptosis is detected which is restricted to the cortex. In order to compare the sites of deletion by endogenous peptide antigen or superantigen we analysed apoptosis in C6 transgenic mice on the CBA/Ca background (carrying the Mtv 8 and 9 integrants recognized by the Vp11 + receptor) and on a C58 background (lacking relevant Mtv integrants) and their non-transgenic littermates Figure 2 (b) shows a moderate number of apoptotic thymocytes localized to the cortex of non-transgenic C58 mice; this is likely to represent negative selection resulting from recognition of self peptides (as in Fig 2a) , deletion of Vp6 + cells by Mtv7 (11) and death by neglect (12) C6 transgenic female mice on the C58 background (Fig. 2c) show a slight increase in cortical thymocyte apoptosis compared with non-transgenic littermates despite the lack of cognate H-Y ligand. This increase may be attributed either to transgenic T cells dying, having failed to interact with ligand (12) or may represent negative selection of transgenic T cells capable of recognizing crossreactive peptides. C58 male transgenic thymus shows a fourfold increase in apoptotic thymocytes localized in the cortex (Fig 2d and Table 1 ). A few apoptotic cells are also found in the medulla, probably representing the minority population which show delayed up-regulation of TCR and become deleted at a late stage. Non-transgenic CBA/Ca thymus shows a few apoptotic thymocytes in both cortex and medulla (Fig. 2e) , female C6 transgenic littermates show a slight increase in the numbers of apototic thymocytes at these sites (Fig. 2f) . The appearance of apoptotic thymocytes in the medullae of the CBA/Ca mice in contrast to the C58 mice is likely to reflect the interaction of Mtv 8 and 9 with Vp11 + cells, resulting in deletion of mature thymocytes in the medulla. In male C6 transgenic CBA/Ca thymus, like C58, apoptotic thymocytes are abundant in the cortex (Fig. 2g) . Some increase in the number of apoptotic medullary thymocytes is also evident in comparison with non-transgenic CBA/Ca mice, probably resulting from the deletion of V p 11 TCR W , CD8 + , SP cells by Mtv 8 and 9 (21) .
Negative selection by cognate antigen can occur at different sites
To confirm the correlation between the site of apoptosis and functional negative selection, we examined another transgenic line expressing a TCR specific for another H-Y epitope, the A1(m-1) line expresses a receptor specific for H-2E k /H-Y, showing a late deletion phenotype with CD4 + SP cells deleted but DP cells unaffected. This may be a consequence of TCR affinity and the pattern of thymic H-Y and H-2E expression Non-transgenic CBA/Ca thymus shows apoptotic cells in the cortex and medulla (Figs 2e and 3a) . A1(m-1) female transgenic thymus is similar except for the 10-fold decrease in apoptotic cells in the medulla due to the relative absence in this Vp8.2 + line of TCR Vp elements capable of interacting with Mtv 8 and 9 carried by CBA/Ca mice (Fig. 3b) . Transgenic male thymus shows the medulla to be densely packed with apoptotic thymocytes (Fig. 3c ) It is theoretically possible that medullary localization of apoptosis is a consequence of this receptor being restricted by MHC class II rather than class I as in the C6 line. We therefore examined thymic sections from the C5 + A18.A transgenic line expressing a MHC class II restricted receptor but showing negative selection at the DP stage, although at a later stage than that in C6 transgenic males. The A18.A transgenic lines express an H-2E k -restricted receptor specific for the C5 complement component which is processed as an exogenous soluble antigen (22) , in contrast to the cellular H-Y epitopes While availability of H-Y epitopes is not limiting (23) (24) (25) , the use of a soluble antigen allowed us to confirm that differences in the site of deletion were not attributable to differences in antigen distribution. CBA/Ca mice produce C5 complement component and therefore delete transgenic thymocytes (15) . The localization of apoptotic thymocytes is as predicted for a TCR transgenic in which the stage of negative selection is intermediate between the C6 line, showing apoptosis in the cortex, and the A1(m-1) line, with apoptosis in the medulla. In C5 + A18.A mice apoptotic thymocytes are increased 4-fold and are distributed equally between cortex and medulla (Fig. 3f) .
Discussion
The localization of apoptotic thymocytes in the transgenic lines clearly shows that negative selection following interaction with self peptide can be entirely cortical or medullary or be distributed between both. The fact that apoptotic medullary thymocytes are rarely detected in Czech mice or in humans (D. C. Douek, unpublished observations) both of which lack Mtv superantigens, suggests that most peptide-mediated negative selection occurs in the cortex. Earlier observations of negative selection limited to the medulla (6, 7, 12) are attributable to the effects of endogenous Mtv 8 and 9. It is unclear whether this indicates that thymic expression of these superantigens is limited to the medulla or that only the more mature thymocytes are able to interact in a manner which causes deletion. Certainly there is evidence that these particular superantigens have a limited pattern of thymic expression (26) . Negative selection in these examples has been assumed to affect DP thymocytes since, despite being a class ll-mediated event, both CD4 SP and CD8 SP cells expressing the specific Vp are generally reduced and yet apoptosis is localized to the medulla which contains few DP Thymic cell suspensions were counted and the cellulanty expressed as a percentage of the cellulanty of non-transgenic littermate thymuses. The number of apqptotic thymocytes in comparable areas of thymic cortex and medulla were counted at high resolution [representative fields (n = 4) are shown in Figs 2 and 3] and the result is expressed as the mean number of apoptotic thymocytes per 0 3 mm 2 (the approximate size of a field).
cells (27) . The most likely explanation for this is that the interaction leading to negative selection occurs at the SP stage in the case of both CD4 + and CD8 + cells. This is compatible with the observations that Mtvs can stimulate peripheral CD8 + T cells and that in CD4~/~mutant mice, Mtvmediated negative selection of CD8 + SP cells is similar to that in wild-type mice Using TCR transgenic lines in which negative selection takes place at different stages of thymocyte maturation, it is shown that the precise site of negative selection can vary and is not dependant on specific antigen-presenting cell types restricted to the cortex, medulla or cortico-medullary junction. The stage of development of thymocytes, principally the surface levels of TCR, and the distribution of cognate peptide are likely to determine the avidity of the interaction of the TCR with the MHC-peptide complex and, consequently, the site of negative selection. The anatomical sites of negative selection are indeed discrete, reflecting such factors as the stage of thymocyte development, access to the deleting ligand, MHC expression by the presenting cell and the avidity of the interaction between these components.
